These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1710 related items for PubMed ID: 11713762

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [Abstract] [Full Text] [Related]

  • 3. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM, Schlom J, Hodge JW.
    Cancer Res; 2002 Oct 15; 62(20):5770-7. PubMed ID: 12384537
    [Abstract] [Full Text] [Related]

  • 4. New prospectives of prostate cancer gene therapy: molecular targets and animal models.
    Hsieh CL, Chung LW.
    Crit Rev Eukaryot Gene Expr; 2001 Oct 15; 11(1-3):77-120. PubMed ID: 11693967
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic vaccines for prostate cancer: a review of clinical data.
    Arlen PM, Gulley JL.
    Curr Opin Investig Drugs; 2005 Jun 15; 6(6):592-6. PubMed ID: 15988910
    [Abstract] [Full Text] [Related]

  • 6. Gene therapy with poxvirus vectors.
    Moroziewicz D, Kaufman HL.
    Curr Opin Mol Ther; 2005 Aug 15; 7(4):317-25. PubMed ID: 16121697
    [Abstract] [Full Text] [Related]

  • 7. Pox viral vaccine approaches.
    Arlen PM, Kaufman HL, DiPaola RS.
    Semin Oncol; 2005 Dec 15; 32(6):549-55. PubMed ID: 16338420
    [Abstract] [Full Text] [Related]

  • 8. [Vaccine therapy of prostate cancer].
    Doehn C, Böhmer T, Sommerauer M, Kausch I, Jocham D.
    Aktuelle Urol; 2005 Sep 15; 36(5):407-16. PubMed ID: 16163603
    [Abstract] [Full Text] [Related]

  • 9. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG.
    Prostate; 2008 May 15; 68(7):715-27. PubMed ID: 18302222
    [Abstract] [Full Text] [Related]

  • 10. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C, Schlom J, Hodge JW.
    Clin Cancer Res; 2005 Mar 15; 11(6):2416-26. PubMed ID: 15788693
    [Abstract] [Full Text] [Related]

  • 11. Poxviruses as vectors for cancer immunotherapy.
    Kwak H, Hörig H, Kaufman HL.
    Curr Opin Drug Discov Devel; 2003 Mar 15; 6(2):161-8. PubMed ID: 12669450
    [Abstract] [Full Text] [Related]

  • 12. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
    Taylor J, Paoletti E.
    Prog Vet Microbiol Immunol; 1988 Mar 15; 4():197-217. PubMed ID: 3078866
    [Abstract] [Full Text] [Related]

  • 13. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S, Lee JB, Lee GK, Chang J.
    Prostate; 2009 Jun 15; 69(9):938-48. PubMed ID: 19267351
    [Abstract] [Full Text] [Related]

  • 14. Antitumor vaccination: where we stand.
    Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S.
    Haematologica; 2000 Nov 15; 85(11):1172-206. PubMed ID: 11074658
    [Abstract] [Full Text] [Related]

  • 15. Advances in specific immunotherapy for prostate cancer.
    Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.
    Eur Urol; 2008 Apr 15; 53(4):694-708. PubMed ID: 18061335
    [Abstract] [Full Text] [Related]

  • 16. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry.
    Skinner MA, Laidlaw SM, Eldaghayes I, Kaiser P, Cottingham MG.
    Expert Rev Vaccines; 2005 Feb 15; 4(1):63-76. PubMed ID: 15757474
    [Abstract] [Full Text] [Related]

  • 17. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM.
    Cancer Res; 2007 Feb 01; 67(3):1344-51. PubMed ID: 17283172
    [Abstract] [Full Text] [Related]

  • 18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA, Hu P, Epstein AL.
    Handb Exp Pharmacol; 2008 Feb 01; (181):291-328. PubMed ID: 18071951
    [Abstract] [Full Text] [Related]

  • 19. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
    Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Ménard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W.
    Clin Cancer Res; 2005 May 01; 11(9):3353-62. PubMed ID: 15867235
    [Abstract] [Full Text] [Related]

  • 20. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors.
    Mastrangelo MJ, Lattime EC.
    Cancer Gene Ther; 2002 Dec 01; 9(12):1013-21. PubMed ID: 12522440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 86.